Antibodies News and Research

RSS

Surrey research offers new hope for people suffering from immunodeficiencies

Several rare immune disorders are caused by mutations in the patient's DNA. The University of Surrey and its collaborators found that targeting the mutated pathways with new drugs offers new hope for people suffering from rare conditions such as immunodeficiencies.

12 Dec 2024

New hepatitis B vaccine offers superior protection for people with HIV

A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn't respond to prior vaccination, according to the results of an international study led by a Weill Cornell Medicine investigator.

11 Dec 2024

Skin-friendly bacteria could revolutionize vaccination

Imagine a world in which a vaccine is a cream you rub onto your skin instead of a needle a health care worker pushes into your one of your muscles.

11 Dec 2024

Next-generation cell-penetrating antibodies could transform cancer treatment

A news feature on the research paper "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition" by Rackear et al. was published in Oncotarget's Volume 15 on November 22, 2024, titled "Advancements in cell-penetrating monoclonal antibody treatment."

11 Dec 2024

Early exposure to parental smoking linked to higher MS risk

Cutting early life exposure to parental smoking may lower the risk of developing MS (multiple sclerosis) in those who are genetically predisposed to the disease, finds research published online in the Journal of Neurology Neurosurgery & Psychiatry.

11 Dec 2024

Interim analysis of STOMP study finds no efficacy for tecovirimat in mild to moderate Mpox cases

The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international clinical trial called the Study of Tecovirimat for Mpox (STOMP).

10 Dec 2024

New vaccine approach shows promise against Hepatitis C

Globally, approximately 58 million people are chronically infected with HCV, resulting in 290,000 annual deaths due to complications such as liver cirrhosis and liver cancer.

6 Dec 2024

Researchers discover new receptor in pain signaling pathway

Researchers at the NYU Pain Research Center have found a new receptor for nerve growth factor that plays an important role in pain signaling, even though it does not signal on its own, according to a study published in the Journal of Clinical Investigation.

6 Dec 2024

PAGER technology unlocks new potential for controlling cellular activity

A basic function of cells is that they act in response to their environments. It makes sense, then, that a goal of scientists is to control that process, making cells respond how they want to what they want.

5 Dec 2024

evitria partners with Sapio Sciences to streamline antibody workflow management and reporting

Sapio Sciences, the science-aware™ lab informatics platform, today announced that evitria, a leader in antibody expression services, has selected Sapio’s Electronic Lab Notebook (ELN) and Sapio Report Builder to enhance its sample tracking, data capture, and reporting capabilities.

4 Dec 2024

evitria Partners with Sapio Sciences to Streamline Antibody Workflow Management and Reporting

evitria optimizes antibody expression services, enhancing data capture and reporting capabilities for scientific workflows with Sapio's ELN and Report Builder,

From Sapio Sciences 4 Dec 2024

How carrageenan affects insulin resistance

A randomized controlled trial found that carrageenan, a common food additive, may cause subclinical inflammation and insulin resistance in overweight individuals, mediated by gut permeability and inflammation. Effects were linked to BMI but not observed in non-overweight participants during short-term exposure.

3 Dec 2024

Beckman Coulter Life Sciences Accelerates Drug Discovery with Launch of Cydem VT Automated Clone Screening System

...

From Beckman Coulter Life Sciences - Flow Cytometry 3 Dec 2024

PD-1 deficiency reveals the impact of checkpoint inhibition on B cell function

A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint inhibitors experience increased susceptibility to common infections.

27 Nov 2024

Late-liver-stage malaria vaccine delivers 89% protection and boosts cellular immunity

Genetically attenuated malaria parasites with extended liver-stage arrest (GA2) showed 89% protection in a clinical trial, surpassing earlier vaccine candidates and highlighting the potential of cellular immunity.

26 Nov 2024

Scientists develop method to study malaria's sticky proteins

Scientists have unveiled a new tool for studying the highly variable traits that allow malaria parasites to stick to red blood cells and evade the immune system.

26 Nov 2024

Brain volume loss linked to Alzheimer's treatment may be caused by amyloid plaque removal

A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue, finds a study led by UCL researchers.

25 Nov 2024

Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell line

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System with RevOpsis Therapeutics ("RevOpsis"), a next-generation biopharmaceutical company spearheading innovation of multispecific biologics in ophthalmic therapies

From Asimov 25 Nov 2024

Researchers develop efficient approach for designing custom proteins

Protein design aims to create customized antibodies for therapies, biosensors for diagnostics, or enzymes for chemical reactions.

22 Nov 2024

Cetuximab performs better than durvalumab in treating head and neck cancers

Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report. Smokers and drinkers, as well as those with HPV infections, are disproportionately affected.

22 Nov 2024